Sanofi wants kids to game their way to diabetes control

A new app from the French drug giant teaches kids with type 1 diabetes how to live with their condition. 

By Sy Mukherjee • Sept. 10, 2014

BMS sues Merck over historic PD-1 cancer drug Keytruda

Merck was first to the finish line with Keytruda approval. But BMS claims it owns the rights to a crucial component of PD-1 inhibition -- and that Merck is in violation of its patent.

By Nicole Gray • Sept. 9, 2014

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

The statin stumper: Are new cholesterol guidelines prudent or overzealous?

There may be controversy surrounding the guidelines -- but the American Heart Association is counting on the AHA/ACC 2013 guidance to save lives.  

By Nicole Gray • Sept. 9, 2014

Roche cuts jobs in Spain in response to price controls

Spanish officials have negotiated lower prices for drugs, as well as how much money the government pays for them.

By Nicole Gray • Sept. 4, 2014

AstraZeneca's Brilinta falls short in phase IV study

But the trial still identified some upsides to using the drug.

By Nicole Gray • Sept. 3, 2014

Novo Nordisk walks away from inflammatory disease R&D

All R&D investment and efforts will now be refocused on Novo’s core business, diabetes.

By Nicole Gray • Sept. 3, 2014

Bayer to finally bring world famous 'hangover cure' Berocca to US

The orange-tinted disc contains vitamins, zinc, and caffeine, and is a favorite pick-me-up for consumers in dozens of countries. But its ostensible hangover-curing effect isn't supported by studies.

By Sy Mukherjee • Sept. 2, 2014

The biosimilars are coming: Tackling uncertainty and interchangeability

The Generic Pharmaceutical Association says biosimilar interchangeability "is the engine that drives generic competition." But how do we create a working definition for it?

By Nicole Gray • Aug. 28, 2014

The biosimilars are coming: Why Basaglar and Zarzio are harbingers of a new pharma landscape

Biosimilars. Follow-on biologics. Subsequent-entry biologics. Call them what you want -- generic versions of branded biologics are a reality. But there's still work to be done on improving these products' approval pathway.

By Nicole Gray • Aug. 27, 2014

Mylan introduces generic of Upsher-Smith's Klor-Con

Mylan continues to build its legacy as a generics powerhouse. 

By Nicole Gray • Aug. 26, 2014

Actavis, UCB Pharma butt heads over generic Neupro

UCB Pharma, the manufacturer of Neupro (rotigotine), is suing Actavis to stop commercialization of rotigotine before the expiration of certain US patents.

By Nicole Gray • Aug. 26, 2014

Pfizer, GSK's Viiv Healthcare nabs FDA approval for 3-in-1 HIV drug

Could ViiV's Triumeq outsell Gilead's own triple-combo, Atripla? 

By Nicole Gray • Aug. 25, 2014

Novartis-funded study shows 75% of asthmatics are at risk

A Novartis-funded survey conducted by Allergy UK finds that patients who think they have mild-to-moderate asthma are dependent on relief inhalers.

By Nicole Gray • Aug. 22, 2014

Jordan-based Hikma Pharma posts strong results amidst regional turmoil

Hikma anticipates a more challenging second half of the year because of political turmoil in Sudan, Iraq, and Libya. But its injectables business is going strong in the US. 

By Nicole Gray • Aug. 22, 2014

The 4 pharma companies with the highest profit margins [Infographic]

Spoiler alert: they aren't the ones you'd expect.

By Sy Mukherjee • Aug. 22, 2014

Hospira wins temporary restraining order against Precedex generics

A federal judge has issued a temporary restraining order blocking the FDA's decision to allow generic versions of Hospira's IV sedative.

By Sy Mukherjee • Aug. 20, 2014

Apricus Biosciences launches topical ED treatment in Germany

Hexal AG -- a Sandoz affiliate -- will market Vitaros (alprostadil) in Germany, where the drug will join a $150 million ED market.

By Nicole Gray • Aug. 20, 2014

Lilly, Boehringer win tentative FDA approval for Sanofi diabetes biosimilar

The provisional nature of the approval for this long-acting insulin is not based on safety concerns, but rather an ongoing patent-infringement spat with Sanofi. 

By Nicole Gray • Aug. 20, 2014

Analysts: Transition to generic antidepressants will be offset by new options

Two new drugs already on the market -- plus one close to launching -- are going to prove useful in a therapeutic category that depends on the availability of new treatment options.  

By Nicole Gray • Aug. 20, 2014

'Ice Bucket Challenge' defies skeptics, raises $22.9M for ALS research

If donations continue at their current pace, the challenge could help raise an entire year's ALS research budget in the next three weeks.

By Sy Mukherjee • Aug. 19, 2014

Eisai files thyroid cancer drug in US, EU

This first-in-class treatment was filed in Japan in late June. It has been granted orphan drug designation in Japan, the EU and the US.

By Nicole Gray • Aug. 19, 2014

Advocates slam NICE, Janssen over prostate cancer drug 'fiasco'

“It’s a fiasco,” said Owen Sharp, CEO of Prostate Cancer UK. “This decision is a kick in the teeth for men with advanced prostate cancer.”

By Nicole Gray • Aug. 19, 2014

Jilting generics: Part 2 of an exclusive interview with GPhA CEO Ralph Neas

Current REMS abuses are already costing more than $5 billion a year in savings. That number could rise sharply if biosimilars are blocked using the same strategy, warns Neas.  

By Nicole Gray • Aug. 17, 2014

UPDATED: FDA issues consumer warning on fake Ebola drugs

"Individuals promoting these unapproved and fraudulent products must take immediate action to correct or remove these claims or face potential FDA action," said the agency on its website. 

By Sy Mukherjee • Aug. 15, 2014

Debt-ridden Dendreon struggles to stay afloat

Dendreon shares have been in free fall since Tuesday. Its stock price has been as low as $1.30 within the last 24 hours.

By Nicole Gray • Aug. 14, 2014